Evidence map›Paper›PMID 38679648›Full record

ReviewJournal of the Egyptian National Cancer Institute2024

miR-939, as an important regulator in various cancers pathogenesis, has diagnostic, prognostic, and therapeutic values: a review.

Hosein Kouchaki, Parnia Kamyab, Farzaneh Darbeheshti, Arezou Gharezade, Hamed Fouladseresht, Reza Tabrizi

Abstract readReview
In one paragraph

Review in Journal of the Egyptian National Cancer Institute, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hosein KouchakiShiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Parnia KamyabUSERN Office, Fasa University of Medical Sciences, Fasa, Iran.
Farzaneh DarbeheshtiDepartment of Radiation Oncology, Dana Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Arezou GharezadeDepartment of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Hamed FouladsereshtDepartment of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. fouladsereshtimmunology@gmail.com.
Reza TabriziClinical Research Development Unit, Valiasr Hospital, Fasa University of Medical Sciences, Fasa, Iran. kmsrc89@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMicroRNAs (miRNAs or miRs) are highly conserved non-coding RNAs with a short length (18-24 nucleotides) that directly bind to a complementary sequence within 3'-untranslated regions of their target mRNAs and regulate gene expression, post-transcriptionally. They play crucial roles in diverse biological processes, including cell proliferation, apoptosis, and differentiation. In the context of cancer, miRNAs are key regulators of growth, angiogenesis, metastasis, and drug resistance. MAIN BODY: This review primarily focuses on miR-939 and its expanding roles and target genes in cancer pathogenesis. It compiles findings from various investigations. MiRNAs, due to their dysregulated expression in tumor environments, hold potential as cancer biomarkers. Several studies have highlighted the dysregulation of miR-939 expression in human cancers.

conclusionOur study highlights the potential of miR-939 as a valuable target in cancer diagnosis, prognosis, and treatment. The aberrant expression of miR-939, along with other miRNAs, underscores their significance in advancing our understanding of cancer biology and their promise in personalized cancer care.

Indexed as

Biomarkers, TumorGene Expression Regulation, NeoplasticMicroRNAsNeoplasmsHumansPrognosisBiomarkers, TumorMicroRNAsMIRN939 microRNA, humanCancerDiagnosticmiR-939PrognosticTherapeutic

Identifiers

PMID38679648
PMCPMC13313853

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.